Arca
Skip to content
Tools
Tools

Secondary hyperparathyroidism

Drug research and approvals for secondary hyperparathyroidism: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 22 studies of secondary hyperparathyroidism are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, FDA has 1 approved and 1 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 22
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 1
  • EU medicines: 3

Recruiting now

Newest posted first, of 22 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 5

Phase 3 3

Phase 2 5

How its trials ended

185 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 52 whose ending is known, 62% met their primary endpoint, 2% missed it and 37% stopped early.

  • Completed, result not reported10155%
  • Met its primary endpoint3217%
  • Ongoing1910%
  • Status unknown137%
  • Stopped: other or unclear95%
  • Stopped: sponsor or business decision53%
  • Stopped: enrollment or feasibility32%
  • Stopped: funding21%
  • Missed its primary endpoint11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Mar 26, 2014A multicenter single-arm extension study to describe the long-term safety of amg 416 (velcalcetide) in the treatment of secondary hyperparathyroidism in…Amg 416 (velcalcetide)AmgenClosed
Jun 13, 2013A multicenter, multiple-dose, two-arm, active-controlled, double-blind, double-dummy study to compare the therapeutic efficacy and safety of oral doses of…Amg 416AmgenOngoing

FDA orphan designations

Approved first, then open designations, newest first
Oct 18, 2016ZemplarIndicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism…Abbvie, inc.Approved
Sep 7, 2016CinacalcetTreatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease receiving dialysisAmgen, Inc.Designated

Medicines authorised in the EU

Newest first
Apr 3, 2020Cinacalcet AccordpharmaCinacalcet · genericAccord Healthcare S.L.U.EMA ↗
Nov 11, 2016ParsabivEtelcalcetideAmgen Europe B.V.EMA ↗
Nov 19, 2015Cinacalcet Viatris (previously Cinacalcet Mylan)Cinacalcet · genericMylan Pharmaceuticals LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.